Our Partners > Platinum Sponsors 2020
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
AbbVie, a global, researched-based biopharmaceutical company, is committed to educating patients and caregivers about Parkinson’s disease to raise awareness about the condition, and further research to improve the lives of those living with and impacted by this disease. AbbVie is a proud sponsor of the Parkinson’s Unity Walk. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com.
ACADIA’s mission is to be the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with central nervous system disorders.
Acorda is proud to support the Parkinson’s Unity Walk, and we are excited to join people with Parkinson’s, their family and friends in April to raise awareness of Parkinson’s. As an emerging leader in Parkinson’s, our goal is to support the Parkinson’s community through medical research, educational initiatives and programs like the Unity Walk that help people with Parkinson’s.
Founded in 1995, Acorda is focused on developing therapies to restore neurological function. We also have a strong commitment to the communities we serve through our extensive outreach programs and advocacy support, providing information and resources to help people with neurological disorders.
This year we are hosting our sixth annual “I Walk Because…” t-shirt booth. “I Walk Because…” is one of Acorda’s first community programs and gives a voice to individuals to celebrate their strength, support and resiliency. Stop by our booth and tell us why you’re walking this year!
Axovant Gene Therapies, is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.
For more information, visit www.axovant.com.
Boston Scientific is a proud sponsor of the 2020 Parkinson’s Unity Walk. Our FDA-approved therapy for patients with Parkinson’s disease is backed by rigorous clinical data and the experiences of our patients around the world. To learn more about DBS from Boston Scientific, and to hear from our patients in their own words, visit DBSandMe.com.
Founded in 1979, Boston Scientific is dedicated to transforming the lives of patients around the world. Each year, our devices treat 22 million patients in over 100 countries. Throughout our history, we've collaborated with healthcare providers to create meaningful solutions that matter to clinicians and patients. Our unwavering commitment to excellence shows up in our product development, manufacturing rigor, and education of clinicians and patients—and ultimately in the devices that go to the patients we serve.
De Oro Devices is an exciting new startup focused on working closely with the Parkinson’s community to develop non-invasive, innovative, easy-to-use solutions that improve lives and increase mobility. Our first device, NexStride, combines research-backed visual and auditory cues into a small, portable accessory that can be attached onto any cane, walker, or walking poles to increase mobility and help with freezing. Get moving again with NexStride at www.getnexstride.com!
We founded De Oro Devices in 2018 with the goal of taking the results of countless scientific research articles and building real products that people with Parkinson’s can use today. We are a small team of 5 and we are honored to be sponsoring the 26th annual Parkinson’s Unity Walk.
LSVT Global, Inc. has researched and developed highly effective speech, physical and occupational therapy programs (LSVT LOUD and LSVT BIG) for people with Parkinson disease. Visit www.lsvtglobal.com to find LSVT Certified Clinicians near you, purchase or rent exercise videos for improving voice and movements, register for free online and live educational events, and learn more about our speech exercise software program. LSVT Global is the world leader in number of therapists trained in a Parkinson-specific approach, with over 40,000 LSVT Certified Clinicians from 73 countries. LSVT LOUD is the gold standard in speech treatment for people with PD, backed by 25+ years of funded research from the National Institutes of Health. LSVT LOUD can now be received in person or via telehealth (eLOUD) or by using our LSVT Companion speech exercise program. The LSVT BIG physical/occupational therapy program empowers people with PD to improve their mobility, balance and function for greater confidence at work, home, and play. During the Unity Walk, meet LSVT LOUD and LSVT BIG world experts at our booth and ask how you can keep your voice and movement alive with LSVT! For more information, visit www.LSVTGlobal.com.
Deep brain stimulation (DBS) development started in 1987 and Medtronic has been the leader in the field ever since, with over 150,000 implanted with Medtronic DBS Therapy. The Medtronic DBS Therapy system has been rigorously tested with clinical evidence and is FDA approved for people with Parkinson’s who had recent onset of movement symptoms as well as those with longer-standing movement symptoms. To learn more about Medtronic DBS Therapy, please visit www.MedtronicDBS.com.
As a global leader in medical technology, services and solutions, Medtronic strives to improve the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes. Join us in our commitment to take healthcare Further, Together.
Medtronic is also generously supporting the new book Ending Parkinson’s Disease. This book highlights the dramatic rise of the disease; its likely cause including environmental factors and what we can do to prevent and end the disease. The first 300 people that stop by the booth will receive an autographed copy of the book. Ending Parkinson’s Disease was written by 4 leading experts in the Parkinson’s field: Bastiaan R. Bloom, MD, PhD, Ray Dorsey, MD, Michael S. Okun, MD, Todd Sherer, PhD. Several of the authors will be in the booth signing books!
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)
Parkinson & Movement Disorder Alliance (PMD Alliance) is a community of movers and motivators working hand-in-hand to bring education and connection to those impacted by movement disorders.
Whether it’s those living with a diagnosis, their care partners, adult children, or support group leaders, we meet the needs of the people we serve by creating solutions to fundamentally enlighten, inform and incite positive change. We’ve built a portfolio of in-person and online programs, calling on the experience and expertise of our physician partners - over 100 movement disorder neurologists from practices large and small across the country.
Our in-person workshops won’t just keep you informed and get you moving. They’ll help you build practical skills and make connections in ways lively and unexpected. Our online programs, with a click, break down the twin barriers of isolation and distance to connect you with an interactive community of experts and allies. Visit www.pmdalliance.org for a full schedule and more information; we can’t wait to meet you!
Supernus, (formerly known as US WorldMeds), is proud to be a Platinum Sponsor at this year’s Parkinson’s Unity Walk. Supernus is committed to supporting people with Parkinson’s and care partners to increase Parkinson’s disease awareness and help improve the quality of care. Click to learn about our three available PD treatment options, our Circle of Care™ Program and our Parkinson’s support initiatives. Please visit https://www.supernus.com/commercial-products
Vertical Pharmaceuticals, LLC is an indirect subsidiary of Osmotica Pharmaceuticals PLC. Vertical Pharmaceuticals is dedicated to the therapeutic areas of neurology and women’s health. Osmotica Pharmaceuticals, the parent company of Vertical Pharmaceuticals, is a publicly held, fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing specialty products. Osmotica Pharmaceuticals is headquartered in Bridgewater, NJ.
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, a monogenic form of ALS called SOD1, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager has strategic collaborations with AbbVie and Neurocrine Biosciences. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.
Click for a printer friendly version